Jinarc (tolvaptan) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Jinarc (tolvaptan) is indicated for the treatment of autosomal dominant polycystic kidney disease (ADPKD).
Conclusion: GoPro® camera proved to be a very interesting tool to document surgerie s without interfering with the procedure and with great educational potential. More studies should be conducted to evaluate the role of this equipment.
Condition: ADPKD Interventions: Drug: Metformin; Drug: Tolvaptan Sponsor: Azienda Ospedaliero-Universitaria Consorziale Not yet recruiting
Conclusions: Hepatomegaly was strongly associated with both death and longer hospital stay due to cyst infection.Nephron
A 60-year-old multi-morbid male patient with polycystic kidney disease and secondary chronic renal insufficiency stage G5 A3 according to Kidney Disease: Improving Global Outcomes (KDIGO) classification was referred to our hospital with radiological differential diagnoses of sarcoidosis, ectasia of the pulmonary arteries, lymphoma, or central bronchial carcinoma with contralateral hilar lymph node metastases. He had concomitant arterial hypertension, manifest osteoporosis due to renal osteopathy, secondary compensated renal hyperparathyroidism, compensated metabolic renal acidosis, and diabetes mellitus type 2.
We examined whether hypothalamic paraventricular nucleus (PVN) activation or circulating vasopressin contribute to hypertension and baroreflex dysfunction in the Lewis polycystic kidney (LPK) rat. Results: Bilateral PVN inhibition with muscimol reduced SBP further in urethane-anaesthetized adult LPK rats than in control Lewis rats (−43 ± 4 vs. −18 ± 3 mmHg; P
CONCLUSIONS: Rigorous clinical observation recognises processes ignored by the medical literature, and the correct application of the scientific method helps identify and reveal new nosological entities, confirming with this story's example that, in medicine, there are no exhausted issues. PMID: 30518488 [PubMed - in process]
Conclusion: ADPKD patients with AMI suffer from more severe conditions and difficult therapies, resulting in a poorer prognosis.Kidney Blood Press Res 2018;43:1806 –1812
PMID: 30484349 [PubMed - as supplied by publisher]
Authors: Suwa Y, Higo S, Nakamoto K, Sera F, Kunimatsu S, Masumura Y, Kanzaki M, Mizote I, Mizuno H, Fujio Y, Hikoso S, Sakata Y Abstract A 70-year-old man with dyspnea was admitted to our department and received standard therapy for recurrent heart failure. He was diagnosed with polycystic kidney disease (PKD) in his thirties and received hemodialysis for 4 years before undergoing renal transplantation at age 45. Although his left ventricular ejection fraction (LVEF) was preserved in his 50s, LVEF decreased progressively from 61% to 24%, while left ventricular diastolic dimension (LVDd) increased from 54 mm to 65 ...
Conclusion: Urinary L-FABP reflects the progression of tubulointerstitial damage, and therefore, may be a useful marker for monitoring the progression of PKD.Kidney Blood Press Res 2018;43:1716 –1729